Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2016-06-20 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
French Regulatory Approval Received 2 pages 211.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 June 2016 from Medical Developments International Limited. It announces the receipt of Marketing Authorisation for a product (Penthrox) in France and discusses the implications for sales and milestone payments. The content is a regulatory announcement about product approval and business development, not a financial report, earnings release, or management discussion. The document length is 4110 characters, which is relatively short and focused on a specific regulatory approval event. There is no financial data, no mention of shareholder votes, no management changes, no legal proceedings, and no detailed financial or operational results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-06-20 English
Construction of new manufacturing facility and Govt grant 2 pages 210.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 June 2016 about the construction of a new manufacturing facility and receipt of a government grant. It discusses the grant amount, the purpose of the grant, the new manufacturing plant, and some company background. There are no financial statements, no quarterly or annual results, no voting results, no management changes, no legal proceedings, no merger or acquisition details, and no detailed financial data. The document is relatively short (3184 characters) and serves as a corporate update or news announcement rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2016-06-15 English
Licensing deal for Canada 2 pages 207.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 June 2016 about a licensing deal for Canada involving Medical Developments International Limited. It discusses a Term Sheet signed with a pharmaceutical company for distribution rights and includes details about upfront and milestone payments. The content focuses on a business development update rather than financial results, regulatory filings, or management changes. The document length is 3141 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not a report or a certification but an announcement of a business transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to a licensing deal and potential revenue streams from the agreement.
2016-06-13 English
Ceasing to be a substantial holder - HHL 3 pages 165.9KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Form 605' and references the Corporations Act 2001 Section 671B, which pertains to notices of ceasing to be a substantial holder. The content includes details about changes in relevant interests, associations, and addresses related to substantial shareholders. It is a regulatory notice about shareholding changes rather than a financial report, earnings release, or management discussion. The document is a formal notification of a change in substantial shareholding status, which aligns with the category of Major Shareholding Notification (MRQ). The document length is 5818 characters, which is sufficient to contain detailed information about the shareholding changes. Therefore, the appropriate classification is MRQ with high confidence.
2016-05-29 English
CEO US Roadshow Presentation 28 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation focused on Medical Developments International's products, market opportunities, clinical benefits, intellectual property, manufacturing, and regulatory progress. It includes sales estimates, product descriptions, clinical trial references, and strategic plans. There is no indication of it being a formal financial report, earnings release, regulatory filing, or legal document. The content is consistent with an investor presentation aimed at providing comprehensive information about the company's business and growth prospects to potential investors. The length and detail support this classification rather than a brief factsheet or announcement. Therefore, the document is best classified as an Investor Presentation (IP).
2016-05-29 English
MVP signs Respiratory deals in the US and Portugal 2 pages 222.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 25 May 2016 about Medical Developments International Limited signing distribution deals in the United States and Portugal. It details new commercial agreements with AmerisourceBergen and OverPharma for respiratory devices. There is no financial data, no mention of report filings, no regulatory certifications, no voting results, no management changes, no legal proceedings, and no merger or acquisition activity. The document is a corporate announcement about business development and distribution deals, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, or more broadly business expansion announcements. Given the content, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters and is a direct announcement, not a report publication notice or certification. Confidence is high due to clear content focus on distribution deals and business expansion.
2016-05-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.